Refereed journal article or data article (A1)

Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis

List of Authors: Katariina Hänninen, Matias Viitala, Teemu Paavilainen, Jari O. Karhu, Juha Rinne, Juha Koikkalainen, Jyrki Lötjönen, Merja Soilu-Hänninen


Publication year: 2020

Journal: Frontiers in Neurology

Journal name in source: FRONTIERS IN NEUROLOGY

Journal acronym: FRONT NEUROL

Volume number: 11

Number of pages: 8

ISSN: 1664-2295

eISSN: 1664-2295


Self-archived copy’s web address:

Purpose:Thalamus is among the first brain regions to become atrophic in multiple sclerosis (MS). We studied whether thalamic atrophy predicts disability progression at 5 years in a cohort of Finnish MS patients. Methods:Global and regional brain volumes were measured from 24 newly diagnosed relapsing MS (RMS) patients 6 months after initiation of therapy and from 36 secondary progressive MS (SPMS) patients. The patients were divided into groups based on baseline whole brain parenchymal (BP) and thalamic atrophy. Standard scores (zscores) were computed by comparing individual brain volumes with healthy controls. Azscore cutoff of -1.96 was applied to separate atrophic from normal brain volumes. The Expanded Disability Status Scale (EDSS), brain magnetic resonance imaging (MRI) findings, and relapses were assessed at baseline and at 2 years and EDSS progression at 5 years. Results:Baseline thalamus volume predicted disability in 5 years in a logistic regression model (p= 0.031). At 5 years, EDSS was same or better in 12 of 18 patients with no brain atrophy at baseline but only in 5 of 18 patients with isolated thalamic atrophy [odds ratio (OR) (95% CI) = 5.2 (1.25, 21.57)]. The patients with isolated thalamic atrophy had more escalations of disease-modifying therapies during follow-up. Conclusion:Patients with thalamic atrophy at baseline were at a higher risk for 5-year EDSS increase than patients with no identified brain atrophy. Brain volume measurement at a single time point could help predict disability progression in MS and complement clinical and routine MRI evaluation in therapeutic decision-making.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.

Last updated on 2022-07-04 at 18:04